CVS faces significant 2025 headwinds, including intense pharmacy competition, threatened new federal government pressures, excessive leverage/debt, plus

CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks are trading lower in possible reaction to UnitedHealth's quarterly revenue miss.

This week's dividend activity included increased payouts from Lakeland Financial (LKFN) and Valero Energy (VLO) as well as declarations from companies such as Citigroup (NYSE:C) and Procter & Gamble (NYSE:PG).

CVS Health ( CVS 4.35%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in 2024, when its shares nose-dived by 43%.

We recently published a list of 10 Firms Dominate Monday Upsurge. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other firms that dominated Monday upsurge.

CVS Health has disclosed plans to lay off another 13 employees who are based at or report to its offices at 151 Farmington Ave., in Hartford.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Piper Sandler named UnitedHealth (NYSE:UNH) and CVS Health (NYSE:CVS) as its top picks in the managed care space, arguing that the duo, among leading players in the Medicare Advantage market, are well positioned to benefit from a potential increase in MA payment rates next year.

Shares of CVS Health Corp. CVS advanced 1.11% to $52.14 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.83% to 5,949.91 and the Dow Jones Industrial Average DJIA rising 1.

CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by a high estimate of $82.00 and a low estimate of $58.00. This current average has decreased by 0.93% from the previous average price target of $68.71.

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.